Vitaliy Kyryk 1 protocol

Tetyana Pivneva Department of Sensory Signalling, Bogomoletz Institute of Physiology, Ukraine, Ukraine,
1 protocol

Oksana Rybachuk Department of Sensory Signalling, Bogomoletz Institute of Physiology, Ukraine, Ukraine,
1 protocol
Dana Savulescu National Institute for Communicable Diseases
4 protocols

Doyel Sen E-Scape Bio Inc
2 protocols

Ralph Boettcher Max Planck Institute for Biochemistry
50 protocols

Talita Melo Hanchuk University of Campinas
4 protocols

Reviewer
Olga Kopach
  • Research associate, Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, University College London, UK
Research focus
  • Neuroscience
  • 1 Author merit

Education

PhD

Lab information

Dmitri Rusakov's lab

Publications

https://scholar.google.co.uk/citations?user=ypSwxBgAAAAJ&hl=en&oi=ao
1 Protocol published
Isolation of Neural Stem Cells from the Embryonic Mouse Hippocampus for in vitro Growth or Engraftment into a Host Tissue
Authors:  Oksana Rybachuk, Olga Kopach, Tetyana Pivneva and Vitaliy Kyryk, date: 02/20/2019, view: 5436, Q&A: 0
For both stem cell research and treatment of the central nervous system disorders, neural stem/progenitor cells (NSPCs) represent an important breakthrough tool. In the expanded stem cell-based therapy use, NSPCs not only provide a powerful cell ...
2 Protocols reviewed
Fluorescence-based Single-cell Analysis of Whole-mount-stained and Cleared Microtissues and Organoids for High Throughput Screening
Authors:  Henrik Renner, Mandy Otto, Martha Grabos, Hans R. Schöler and Jan M. Bruder, date: 06/20/2021, view: 1172, Q&A: 1

Three-dimensional (3D) cell culture, especially in the form of organ-like microtissues (“organoids”), has emerged as a novel tool potentially mimicking human tissue biology more closely than standard two-dimensional culture. Typically,

...
More >
A Parkinson’s Disease-relevant Mitochondrial and Neuronal Morphology High-throughput Screening Assay in LUHMES Cells

Parkinson’s disease is a devastating neurodegenerative disorder affecting 2-3% of the population over 65 years of age. There is currently no disease-modifying treatment. One of the predominant pathological features of Parkinson’s disease

...
More >
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.